The cases were confirmed with the real-time reverse transcription polymerase chain reaction (RT-PCR), one of the most accurate laboratory methods for detecting, tracking, and studying COVID-19. An 81% decrease was observed in confirmed cases of symptomatic COVID 19 with REGEN-COV compared to placebo on day 29 in cases where RT-PCR was negative and seronegative Zahnarzt Zürich at the start of the study . In the total trial population, there was a 62% decrease in symptomatic COVID cases confirmed by RT-PCR 19 in the REGEN-COV group compared to placebo on day 29. In total, 145 (98.0%) patients in the prophylaxis group experienced 1,796 episodes of AE and 146 patients (96.7%) in the preventive group experienced episodes of AE in 2009. This study showed that T cell reactions and neutralizing antibodies 25 increased significantly with preventive therapy compared to antiviral prophylaxis. With the advent of early-developing CMV vaccines that are not yet in clinical use, it may be feasible to cause these reactions without the risk of CMV replication inherent in preventive therapy. Post-hoc analyzes include viremia in patients in the preventive therapy group and innovative CMV disease within 100 days and use of valganciclovir during and after the study intervention period in both groups. The choice of anticoagulants should be guided by the patient's comorbidities and the consequences related to COVID-19, including kidney failure, liver damage and coagulopathy, resulting in a risk of bleeding. In addition, such analyzes should reflect "indirect" costs, including those related to the use of medical devices, the management of the adverse effects of prophylaxis, the treatment of ganciclovir-resistant CMV disease, and the impact of indirect effects of CMV The conceptual principles that form the basis of preventive therapy are that it is aimed at high-risk patients, that it is time to be the most effective in breaking an impending disease and that it is administered for a defined duration, generally short. However, the first question is whether preventive therapy is effective and whether the efficacy is comparable to that of universal prophylaxis. The numerical reduction in hospitalization time in prophylaxis compared to the preventive group may be due to more effective prevention of CMV infection and disease and may lead to a further reduction in treatment costs. The use of preventive therapy, compared to antiviral prophylaxis, reduced the incidence of CMV disease for 12 months. You would not get regular maintenance if you have healthy teeth…